Search Result

Results for "

Staphylococcus aureus spp.

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (3) Bacterial (10) Biochemical Assay Reagents (1) Drug Metabolite (1) Reactive Oxygen Species (ROS) (1)
By Research Areas:	Cancer (2) Infection (10) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16911

AFN-1252 Maximum Cited Publications 11 Publications Verification API-1252; Debio 1452	Bacterial Antibiotic	Infection
AFN-1252 is an orally active and selective inhibitor of FabI, an essential enzyme in fatty acid biosynthesis in Staphylococcus spp. AFN-1252 exhibits exquisite and highly selective activity against Staphylococcus spp. AFN-1252 exhibits typical MIC₉₀ values of ⩽0.015 μg/ml against diverse clinical isolates of S. aureus. AFN-1252 is efficacious in a mouse model of septicemia providing 100% protection from an otherwise lethal peritoneal infection of S. aureus Smith .

HY-103249

Reutericyclin Reutericycline	Bacterial	Infection Metabolic Disease
Reutericyclin (Reutericycline) is an orally active antibacterial and anti-obesity agent that selectively inhibits Gram-positive bacteria. By selectively dissipating transmembrane potential, Reutericyclin exerts non-lytic bactericidal or bacteriostatic activity against pathogens such as Clostridium difficile and Staphylococcus aureus, and rapidly kills vegetative cells and spores of Clostridium difficile. Reutericyclin possesses favorable properties including resistance to enzymatic hydrolysis, iron-chelating function, and poor absorption by colonic epithelium. Reutericyclin not only eradicates staphylococcal biofilms and inhibits drug-resistant strains, but also counteracts Risperidone (HY-11018)-induced weight gain by inducing changes in gut microbiota composition and restoring energy utilization efficiency. Reutericyclin can be used in research related to Clostridium difficile infection, Risperidone-induced weight gain, and staphylococcal superficial skin infections .

HY-W412175

Coproporphyrin III dihydrochloride 2 Publications Verification Zincphyrin dihydrochloride	Bacterial	Infection
Coproporphyrin III dihydrochloride is a bioactive molecule excreted by nostril- and skin-associated Propionibacterium species that induces aggregation of Staphylococcus aureus (conditions: during early stationary phase growth, low pH: 4-6). Coproporphyrin III dihydrochloride also induces plasma-independent biofilm formation on abiotic surfaces by Staphylococcus aureus. Coproporphyrin III dihydrochloride may be an important mediator of S. aureus accumulation and/or biofilm formation in the nostrils or other sites where Propionibacterium and S. aureus inhabit .

HY-W010989

Gly-His-Lys acetate	Biochemical Assay Reagents Bacterial	Infection Neurological Disease Inflammation/Immunology Cancer
Gly-His-Lys acetate is a natural, circulating regulatory and antimicrobial tripeptide derived from extracellular matrix proteins. Gly-His-Lys acetate binds Cu ²⁺ to support copper enzyme activation, antioxidant processes, cellular bioenergetics, and the synthesis of elastin, collagen and catecholamines. Gly-His-Lys acetate regulates cell growth, differentiation and tissue repair, and exerts regenerative, anxiolytic, anti-inflammatory, analgesic and immunosuppressive activities. Gly-His-Lys acetate induces liver degenerative changes. Gly-His-Lys acetate can be used for the research of infections, anxiety, pain-related behaviors and immune-associated liver diseases .

HY-127072

Amicoumacin A	Antibiotic Bacterial	Infection Inflammation/Immunology Cancer
Amicoumacin A is an orally active antibiotic. Amicoumacin A targets bacterial ribosomes and inhibits bacterial translation by stabilizing the interaction between mRNA and ribosomes. Amicoumacin A induces cancer cell death by targeting eukaryotic ribosomes. Amicoumacin A exhibits anti-inflammatory and anti-ulcer activities, inhibits carrageenan-induced paw edema, and prevents stress-induced gastric ulcers. Amicoumacin A inhibits the growth of Gram-positive bacteria, Salmonella spp., Shigella spp., Helicobacter pylori, and methicillin-resistant Staphylococcus aureus. Amicoumacin A can be used in the research of lung cancer, breast cancer, bacterial infections, inflammatory edema and gastric ulcers ^[2] .

HY-114622

AFN-1252 tosylate API-1252 tosylate; Debio 1452 tosylate	Bacterial Antibiotic	Infection
AFN-1252 (API-1252) tosylate is an orally active and selective inhibitor of FabI, an essential enzyme in fatty acid biosynthesis in Staphylococcus spp. AFN-1252 tosylate exhibits exquisite and highly selective activity against Staphylococcus spp. AFN-1252 tosylate exhibits typical MIC₉₀ values of 0.015 μg/ml against diverse clinical isolates of S. aureus. AFN-1252 tosylate is efficacious in a mouse model of septicemia providing 100% protection from an otherwise lethal peritoneal infection of S. aureus Smith .

HY-125042

Sarothralin G	Bacterial	Infection
Sarothralin G is an antibacterial compound isolated from Hypericum japonicum Thunb. (Japanese spurfle). The structure of Sarothralin G contains phenolic and aromatic acid moieties and shows excellent antibacterial activity against Gram-positive bacteria such as Staphylococcus aureus, Bacillus subtilis and Nocardia spp., which is stronger than Sarothralen A, B and Saroaspidin A, B, C. Sarothralin G exhibits significant antibacterial potential.

HY-123508

PD 131628	Drug Metabolite Bacterial	Infection
PD 131628 is an antimicrobial agent and active PD 131112 metabolite. PD 131628 is two- to four-fold more active than Ciprofloxacin (HY-B0356), inhibiting all strains of Staphylococcus aureus and Streptococcus pneumoniae. PD 131628 is very active against Neisseria spp., Haemophilus influenzae and Moraxella catarrhalis, with MIC₉₀s ranging from 0.004 to 0.008 mg/L .

HY-181686

Antibacterial agent 326	Bacterial Reactive Oxygen Species (ROS)	Infection
Antibacterial agent 326 is a bactericide that inhibits the growth of various bacterial strains. Antibacterial agent 326 inhibits biofilm formation in Escherichia coli, disrupts bacterial cell membranes, induces oxidative stress and lipid peroxidation in Escherichia coli, increases ROS levels, and reduces GSH activity. Antibacterial agent 326 can be used in studies of bacterial infections, including those caused by Escherichia coli, Staphylococcus aureus, Enterococcus faecalis, Listeria spp., Bacillus subtilis, Serratia marcescens, Salmonella enteritidis and Acinetobacter calcoaceticus .

HY-116558

E-4441	Bacterial	Infection
E-4441 is an orally active Antibacterial agent. E-4441 exerts broad-spectrum in vitro antibacterial activity against Gram-positive bacteria and aerobic bacteria. E-4441 exhibits protective effects against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa infections. E-4441 can be used in the research of systemic bacterial infections (Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa infections) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-103249

Reutericyclin Reutericycline	Infection Structural Classification Microorganisms Classification of Application Fields Antibiotics Antibacterial Disease Research Disease Research Fields Other Antibiotics Source Classification	Bacterial
Reutericyclin (Reutericycline) is an orally active antibacterial and anti-obesity agent that selectively inhibits Gram-positive bacteria. By selectively dissipating transmembrane potential, Reutericyclin exerts non-lytic bactericidal or bacteriostatic activity against pathogens such as Clostridium difficile and Staphylococcus aureus, and rapidly kills vegetative cells and spores of Clostridium difficile. Reutericyclin possesses favorable properties including resistance to enzymatic hydrolysis, iron-chelating function, and poor absorption by colonic epithelium. Reutericyclin not only eradicates staphylococcal biofilms and inhibits drug-resistant strains, but also counteracts Risperidone (HY-11018)-induced weight gain by inducing changes in gut microbiota composition and restoring energy utilization efficiency. Reutericyclin can be used in research related to Clostridium difficile infection, Risperidone-induced weight gain, and staphylococcal superficial skin infections .

HY-127072

Amicoumacin A	Structural Classification Microorganisms Antibiotics Other Antibiotics Source Classification	Antibiotic Bacterial
Amicoumacin A is an orally active antibiotic. Amicoumacin A targets bacterial ribosomes and inhibits bacterial translation by stabilizing the interaction between mRNA and ribosomes. Amicoumacin A induces cancer cell death by targeting eukaryotic ribosomes. Amicoumacin A exhibits anti-inflammatory and anti-ulcer activities, inhibits carrageenan-induced paw edema, and prevents stress-induced gastric ulcers. Amicoumacin A inhibits the growth of Gram-positive bacteria, Salmonella spp., Shigella spp., Helicobacter pylori, and methicillin-resistant Staphylococcus aureus. Amicoumacin A can be used in the research of lung cancer, breast cancer, bacterial infections, inflammatory edema and gastric ulcers ^[2] .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.

Staphylococcus aureus spp.

Inhibitors & Agonists

NaturalProducts

Natural
Products